Search Results

Findings shows animal models show that a U.S. Food and Drug Administration (FDA)-approved antibiotic regimen for multidrug-resistant (MDR) tuberculosis (TB) may not work for TB meningitis.
Biotechnology

FDA-Approved TB Regimen May Not Work Against Deadliest Form of TB Due to Multidrug-Resistant Strains

MBT Desk
3 min read
Tuberculosis, caused by the bacteria Mycobacterium tuberculosis, is a global public health threat. According to the WHO, it is one of the leading killers by a single infectious agent.
Image of a capsules of red and white color in hands of a person wearing surgical gloves along with graphics of bacteria.
India

Prevalence of Multidrug-Resistant Organisms Highest in Indian Patients: Study

MBT Desk
2 min read
A Lancet eClinical Medicine study warns that India is the global hotspot of multidrug-resistant organisms, calling for urgent antibiotic stewardship reforms.
The Joint Panel comprised 25 global experts in pulmonary medicine, infectious diseases, pediatrics, epidemiology, and public health (Representational Image: Freepik)
Medicine

New Guidelines for Drug-Susceptible and Drug-Resistant TB: Shorter, Safer and All-Oral Regimens

Dr. Disha Merlyn Mathias
3 min read
An official update in the treatment of both drug-susceptible and drug-resistant TB by the international panel of experts: ATS/CDC/ERS/IDSA
Antibiotics have been invaluable in the fight against bacterial infections, but bacteria are becoming more and more resistant to them
Fitness and Wellness

A New Treatment for Multidrug-Resistant Bacteria

MBT Desk
3 min read
A new type of drug could provide a way to treat multidrug-resistant bacteria, according to a study published in Nature Communications.
BPaL’s 6-month regimen for drug-resistant TB to be launched nationwide in January after training sessions conclude. (Wikimedia Commons)
Medicine

National TB Elimination Programme Prepares for Launch of Shortest Drug-Resistant TB Treatment BPaL

Ankur Deka
2 min read
Six-month regimen expected to improve treatment outcomes; training sessions underway for doctors across Indian states
India introduced the BPaLM regimen for MDR-TB, which includes Bedaquiline, Pretomanid, Linezolid, and (with or without) Moxifloxacin. It is a newer, shorter regimen, often completed in less than 6 months. ( Representational image : Unsplash )
Medicine

India Targets TB Elimination By 2025: New BPaLM Regimen For Drug-Resistant TB

Yash Kiran Kamble
3 min read
Tuberculosis (TB) remains one of the world's deadliest infectious diseases, particularly in developing regions
Read More
logo
Medbound Times
www.medboundtimes.com